Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hypothalamic Obesity: full-pipeline trial registry
4 of 6 indexed Hypothalamic Obesity trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 4 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Hypothalamic Obesity: 6 US clinical trials tracked, 4 recruiting.
Hypothalamic Obesity is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Rhythm Pharmaceuticals, running 3 of these trials.
Enrollment posture brief
Registry condition hypothalamic-obesity
OPEN 4 | RECR 67% | LATE 3 | EARLY 3 | RANK #2866 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Adenocarcinoma of Lung (67% recruiting · 6 trials)
Hypothalamic Obesity lists 4 open slots (67% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hypothalamic Obesity on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hypothalamic Obesity is recruiting above its size-band peers.
4 of 6 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Hypothalamic Obesity research.
Rhythm Pharmaceuticals accounts for 3 of 6 trials (50%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Hypothalamic Obesity trials plan to enrol fewer than 100 people.
Median target enrolment is 39 among the 6 trials that report a genuine target (sentinel values excluded). 4 of those (66.7%) plan for fewer than 100 participants.
-
Hypothalamic Obesity research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
Rhythm Pharmaceuticals
NCT06239116
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Rhythm Pharmaceuticals
NCT06760546
Tirzepatide in PWS, HO and GNSO
Grace Kim
NCT06901245
Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity
Seattle Children's Hospital
NCT06299891
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals
NCT05774756
Effects of Exenatide on Hypothalamic Obesity
Children's Hospitals and Clinics of Minnesota
NCT01061775
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hypothalamic Obesity records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hypothalamic Obesity trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hypothalamic Obesity page
6 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Hypothalamic Obesity trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Rhythm Pharmaceuticals sponsors the most Hypothalamic Obesity trials on record, review their full trial history before evaluating a specific study. See Rhythm Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hypothalamic Obesity condition card totals 6 registered trials; most-linked intervention Setmelanotide; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.